Patients with relapsed/refractory CLL who received zanubrutinib achieved significantly superior PFS compared with ibrutinib. The prescribing information for Brukinsa ® (zanubrutinib) has been updated ...
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective PFS depends on evaluation of ...
Final CEPHEUS transplant-ineligible analysis showed 72-month PFS of 59.3% with DVRd versus 38.3% with VRd; median PFS was unreached versus 50.2 months (HR 0.55). MRD negativity improved with DVRd at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results